Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Case Report

A Case Report of Conversion from Hashimoto’s Thyroiditis to Graves’ Disease in Type 1 Diabetic Patient Following the COVID-19 Vaccination

Author(s): Işılay Taşkaldıran*, Feride Pınar Altay, Yusuf Bozkuş, Özlem Turhan İyidir, Aslı Nar and Neslihan Başçıl Tütüncü

Volume 23, Issue 3, 2023

Published on: 26 August, 2022

Page: [405 - 409] Pages: 5

DOI: 10.2174/1871530322666220616104058

Price: $65

Abstract

Background: A considerable number of COVID-19 vaccines became available following the outbreak. Yet, various inflammatory and autoimmune complications have been reported following vaccination. We aimed to report the case of a type 1 diabetic patient converting from Hashimoto’s thyroiditis to Graves’ disease after the fourth dose of COVID-19 vaccine, thought to trigger an autoimmune/inflammatory syndrome induced by adjuvants (ASIA syndrome).

Case Presentation: A thirty-one-year-old female patient with type 1 diabetes and Hashimoto’s thyroiditis applied to our clinic with complaints of palpitations, anxiety, and weight loss one month after the fourth dose of COVID-19 vaccine (2 doses of CoronaVac + 2 doses of Pfizer/BioNTech). She was receiving levothyroxine 50 mcg/day. When her thyroid function tests showed thyrotoxicosis, we initially considered thyroxine-related exogenous thyrotoxicosis. However, we considered Graves’ disease upon persisting thyrotoxicosis despite thyroxine withdrawal, positive serum TSH receptor antibody titers, and other imaging findings. Therefore, various autoimmune and inflammatory events have been reported after the COVID-19 vaccination. Adjuvants in vaccines can trigger autoimmune events, which lead to ASIA syndrome. COVID-19 vaccines may cause increased TSH receptor antibody levels or change the balance in the activity of blocking and stimulating antibodies, which may cause a conversion from Hashimoto’s to Graves’ disease.

Conclusion: This was the first case report where the patient experienced a conversion from Hashimoto’s to Graves’ disease after COVID-19 vaccination, which may ultimately be related to ASIA syndrome. Yet, more data is needed to elucidate such a relationship, and patients should closely be checked regularly after four doses of vaccination.

Keywords: ASIA syndrome, COVID-19 vaccine, Graves’ disease, Hashimoto’s thyroiditis, SARS-CoV2, type 1 diabetes.

Graphical Abstract
[1]
Locht, C. Vaccines against COVID-19. Anaesth. Crit. Care Pain Med., 2020, 39(6), 703-705.
[http://dx.doi.org/10.1016/j.accpm.2020.10.006] [PMID: 33096260]
[2]
Polack, F.P. Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C.; Bailey, R.; Swanson, K.A.; Roychoudhury, S.; Koury, K.; Li, P.; Kalina, W.V.; Cooper, D.; Frenck, R.W., Jr; Hammitt, L.L.; Türeci, Ö.; Nell, H.; Schaefer, A.; Ünal, S.; Tresnan, D.B.; Mather, S.; Dormitzer, P.R.; Şahin, U.; Jansen, K.U.; Gruber, W.C. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med., 2020, 383(27), 2603-2615.
[http://dx.doi.org/10.1056/NEJMoa2034577] [PMID: 33301246]
[3]
Kahaly, G.J.; Hansen, M.P. Type 1 diabetes associated autoimmunity. Autoimmun. Rev, 2016, 15, 644e8.
[http://dx.doi.org/10.1016/j.autrev.2016.02.017]
[4]
Kakleas, K.; Soldatou, A.; Karachaliou, F.; Karavanaki, K. Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus (T1DM). Autoimmun. Rev., 2015, 14(9), 781-797.
[http://dx.doi.org/10.1016/j.autrev.2015.05.002] [PMID: 26001590]
[5]
Gonzalez-Aguilera, B.; Betea, D.; Lutteri, L.; Cavalier, E.; Geenen, V.; Beckers, A.; Valdes-Socin, H. Conversion to graves disease from Hashimoto thyroiditis: A study of 24 patients. Arch. Endocrinol. Metab., 2018, 62(6), 609-614.
[http://dx.doi.org/10.20945/2359-3997000000086] [PMID: 30624501]
[6]
McLachlan, S.M.; Rapoport, B. Thyrotropin-blocking autoantibodies and thyroidstimulating autoantibodies: Potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. Thyroid 2013, 23, 14e24.
[7]
Tran, H.A.; Reeves, G.E.M. The influence of hepatitis C infection and interferon-α therapy on thyrotropin blocking and stimulating autoantibodies in Graves’ ophthalmopathy: A case report. Thyroid Res., 2009, 2(1), 12.
[http://dx.doi.org/10.1186/1756-6614-2-12] [PMID: 19954547]
[8]
Daniels, G.H.; Vladic, A.; Brinar, V.; Zavalishin, I.; Valente, W.; Oyuela, P.; Palmer, J.; Margolin, D.H.; Hollenstein, J. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J. Clin. Endocrinol. Metab., 2014, 99(1), 80-89.
[http://dx.doi.org/10.1210/jc.2013-2201] [PMID: 24170099]
[9]
Vera-Lastra, O.; Ordinola Navarro, A.; Cruz Domiguez, M.P.; Medina, G.; Sánchez Valadez, T.I.; Jara, L.J. Two cases of graves’ disease following SARS-CoV-2 vaccination: An autoimmune/inflammatory syndrome induced by adjuvants. Thyroid, 2021, 31(9), 1436-1439.
[http://dx.doi.org/10.1089/thy.2021.0142] [PMID: 33858208]
[10]
İremli, B.G.; Şendur, S.N.; Ünlütürk, U. Three cases of subacute thyroiditis following SARS-CoV-2 vaccine: Postvaccination ASIA syndrome. J. Clin. Endocrinol. Metab. 2021, 106(9), 2600-2605.
[http://dx.doi.org/10.1210/clinem/dgab373] [PMID: 34043800]
[11]
Patrizio, A.; Ferrari, S.M.; Antonelli, A.; Fallahi, P. A case of Graves’ disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination. J. Autoimmun., 2021, 125, 102738.
[http://dx.doi.org/10.1016/j.jaut.2021.102738] [PMID: 34653776]
[12]
Shoenfeld, Y.; Agmon-Levin, N. ‘ASIA’ - autoimmune/inflammatory syndrome induced by adjuvants. J. Autoimmun., 2011, 36(1), 4-8.
[http://dx.doi.org/10.1016/j.jaut.2010.07.003] [PMID: 20708902]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy